Fibrinogen gamma and response to thrombolytic therapy in acute ischemic stroke

Fibrinogen gamma and response to thrombolytic therapy in acute ischemic stroke - Fibrinogen gamma

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON34726

Enrollment

Registered

2010-06-10

Start date

2010-01-01

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ischemic stroke stroke

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: -a clinical diagnosis of acute ischaemic stroke - a measurable deficit on the NIHSS or NIHSS supplemental motor score - treatment with intravenous or intra-arterial alteplase

Exclusion criteria

Exclusion criteria: contra-indications for treatment with iv or ia rt-PA, i.e. -cerebral infarction within the previous 6 weeks, -a history of intracerebral hemorrhage, -severe head injury the previous 4 weeks, -major surgery, gastrointestinal bleeding or urinary tract bleeding within the previous 2 weeks -arterial blood pressure > 185/110 mmHg, -blood glucose 22.2 mmol/l, -clinical signs of hemorrhagic diathesis or platelet count 50 sec or INR >1.7.

Design outcomes

Primary

Measure	Time frame
Neurological improvement by means of the NIHSS at 24 hours and discharge.	—

Secondary

Measure	Time frame
The extent of fibrinogen breakdown measured by markers of fibrinolysis (such as plasma D-dimer concentrations).	—

Countries

Netherlands

Outcome results